Glenmark Pharmaceuticals has informed that it attached media release titled ‘Glenmark Therapeutics Inc., USA launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% (OTC)’.
The above information is a part of company’s filings submitted to BSE.